2月11日，港股医药有所分化。创新药大面积回调，创新药纯度100%的港股通创新药ETF（520880）微 跌0.19%止步三连阳。医疗主题板块继续上行，港股通医疗ETF华宝（159137）走出四连涨，站上20日 均线。 | 分时 多日 1分 5分 15分 30分 · 给会屏 F9 后复农 超级盘加 面试 工具 @ (1) > | | 港般通医疗ETF华宝 | | 159137 | | --- | --- | --- | --- | --- | | 159137.SZ[桃投通四疗ETF华宜] 2026/02/11 歌 1.024 幅0.49%(0.005) 开 1.025 高 1.030 低 1.019 均回 | | | | | | MAS 1.0021 MA10 0.998 MA20 1.022 2026/01/12-2026/02/11(23日)▼ | | 0 | | +0.005 +0.499 | | | 1,160 | SZSE CNY 15:00:00 闭槽 | | T+0 / 0 | | 4-1,152 | | 净值走势 | | 华宝中证港股通医疗主题ETF | | | | DEF | -51.86 ...

Core Viewpoint - The AI medical sector experienced a decline of 0.66% on February 11, with QianYuan Pharmaceutical leading the drop. The Shanghai Composite Index rose by 0.09%, while the Shenzhen Component Index fell by 0.35% [1]. Group 1: Market Performance - The closing price of QianYuan Pharmaceutical was 11.44, down by 4.67%, with a trading volume of 209,800 shares and a transaction value of 243 million [2]. - The AI medical sector saw a net outflow of 1.345 billion from major funds, while retail investors contributed a net inflow of 1.14 billion [2][3]. Group 2: Individual Stock Performance - YoukeDe (688158) closed at 37.54, up by 5.12%, with a trading volume of 631,000 shares and a transaction value of 2.36 billion [1]. - AidiTe (301580) closed at 55.18, up by 4.63%, with a trading volume of 46,100 shares and a transaction value of 251 million [1]. - SanNuo Biology (300298) closed at 18.54, up by 2.71%, with a trading volume of 105,200 shares and a transaction value of 194 million [1]. - The top decliners included QianYuan Pharmaceutical (300254) and KaiPu Biology (300639), with declines of 4.67% and 4.23%, respectively [2].

Core Viewpoint - The company Kaile Co., Ltd. (301070) is expected to achieve a net profit of between 7.7 million to 10 million yuan for the year 2025, marking a successful turnaround from losses to profits, driven by overseas market expansion, improved gross margins, and cost reduction measures [1][2]. Group 1: Performance and Business Operations - The company announced its 2025 annual performance forecast on January 29, 2026, projecting a net profit attributable to shareholders of 7.7 million to 10 million yuan, indicating a turnaround from previous losses [2]. - The improvement in performance is attributed to the expansion into overseas markets, an increase in gross margins, and effective cost-cutting measures [2]. Group 2: Stock Performance - On February 9, 2026, the stock price of Kaile Co., Ltd. rose by 5.01%, closing at 63.08 yuan per share, with a total market capitalization of 5.692 billion yuan and a trading volume of 104 million yuan, reflecting a turnover rate of 2.84% [3]. - The stock also experienced a prior increase of 5.35% on February 3, 2026 [3]. Group 3: Business Development - The company's AI medical business has made progress by jointly launching a solid tumor report assessment system with Huawei, which is expected to scale in more medical scenarios, showcasing the company's efforts in business diversification [4]. Group 4: Institutional Holdings - As of September 30, 2025, the Qiangguo Fund's Qiangguo Xuyuan three-year holding mixed A fund was among the top ten circulating shareholders, holding 3.3874 million shares. On February 9, 2026, during the stock price increase, this fund realized a floating profit of approximately 10.1962 million yuan [5]. Group 5: Financial Situation - As of January 29, 2026, the company's total margin financing and securities lending balance was 434 million yuan, with the financing balance accounting for 8.39% of the circulating market value, indicating a relatively high level [6].

Group 1 - The stock price of Wuzhou Medical (301234) showed volatility from February 4 to February 11, 2026, with a closing price of 42.01 yuan on February 10, reflecting a daily increase of 0.26%, and a latest price of 41.80 yuan on February 11, indicating a decrease of 0.50% [1] - On February 10, the net outflow of main funds was 362.88 thousand yuan, accounting for 14.62% of the total transaction amount, with an overall trend of net outflow in the past five days [1] - The technical indicators show that the current stock price is close to the 20-day resistance level of 42.24 yuan, with a recent MACD indicator showing a golden cross signal, although the distribution of shares is scattered, indicating low control by main funds [1] Group 2 - Recent policies in the medical industry may indirectly impact Wuzhou Medical, with the launch of the China International Medical Equipment and Devices Trading Platform on February 10, aimed at promoting global trade in medical devices, which could benefit the company as its overseas revenue accounts for 96.88% based on the 2024 annual report [2] - The Ministry of Industry and Information Technology and other departments have strengthened policy support for low-altitude economy and AI medical fields, although the company's business is not directly involved in these hot concepts [2] Group 3 - Wuzhou Medical released its 2025 annual performance forecast on January 29, 2026, expecting a net profit range of 16 million to 21 million yuan, representing a year-on-year decline of 47.46% to 59.97%, primarily due to fluctuations in its main business [3] - The company's third-quarter report for 2025 indicated a year-on-year decrease of 46.09% in net profit attributable to the parent company [3]

Company Fundamentals - The company reported a net loss of 6.4264 million HKD for the fiscal year 2025 mid-term, with a year-on-year increase in losses of 55.86% [2] - The main business remains focused on bio-composite fertilizers, while the AI medical business has not yet generated significant revenue, putting pressure on short-term performance improvement expectations [2] Financial Situation - Market liquidity is insufficient, leading to low trading activity; on February 11, the trading volume was only 27,700 HKD, with a turnover rate of 0.01%, indicating that retail investors dominate trading while institutional interest is weak [3] Stock Price Situation - The technical indicators are weak, with the stock price having fallen below multiple moving averages, and MACD and other indicators suggest short-term momentum is sluggish, reflecting a lack of market confidence [4] Industry Policy Status - Despite favorable policies emerging for the AI medical industry, market funds are more inclined towards established leading companies that have achieved commercialization. The AI medical projects of the company are still in the research and development investment phase, and it will take time to realize profitability, making the current negative price-to-earnings ratio unattractive for new capital [5] Market Environment - The market environment for Hong Kong stocks exerts certain pressure on small-cap stocks. The company's total market capitalization is approximately 662 million HKD, categorizing it as a small-cap stock, which tends to see funds flow towards larger, more liquid, and fundamentally stable companies during industry upswings [6]

近期，随着创新药企业陆续披露2025年报及业绩预告，多家企业展现出良好的经营改善态势，在报告期 内实现亏损收窄甚至业绩转正，释放出积极信号。在此背景下，创新药及相关板块再引关注。公告显 示，工银瑞信中证港股通医疗主题交易型开放式指数证券投资基金（简称：港股通医疗ETF工银；代 码：159167）将于2026年2月12日起在深交所上市交易。 公开资料显示，港股通医疗ETF工银（159167）紧密跟踪中证港股通医疗主题指数（代码： 932069.CSI），该指数锚定医疗创新，全面覆盖港股"CXO +互联网医疗+医疗器械+创新药"等医药各领 域核心龙头，并囊括脑机接口、AI医疗、高端医疗器械等热门主题；该指数弹性足，估值具有吸引 力。Wind数据显示，截至2026年2月10日，中证港股通医疗主题指数目前市盈率（TTM）为32.85倍， 处于发布以来48.16%分位，指数当前或未被高估，或仍具有吸引力。 国金证券指出，2025年中国新药License-out交易数量达158笔、总规模1357亿美元，创近十年新高；出 海BD繁荣不仅显著提振短期业绩预期，更推动国产新药国际化开发进程与远期价值提升。申万宏源研 究研报观点 ...

Group 1 - The core viewpoint is that the Hong Kong pharmaceutical sector is experiencing a strong resurgence, driven by the innovative drug industry chain, particularly led by Innovent Biologics [1][8] - The Hong Kong Stock Connect Innovative Drug ETF (520880) reached a peak of 3.86% and closed up 2.9%, recovering the 20-day moving average with a trading volume of 590 million yuan [1][8] - The Hong Kong Stock Connect Medical ETF (159137), which has a high CXO content, rose by 2.1%, marking its sixth consecutive day of gains [1][8] Group 2 - The Chinese innovative drug sector is witnessing a robust international expansion, with significant business development (BD) transactions occurring [4][10] - Notable collaborations include Innovent Biologics' announcement of a global strategic partnership with Eli Lilly worth up to $8.85 billion, including an upfront payment of $350 million [4][10] - In January, CSPC Pharmaceutical Group entered a platform-level collaboration with AstraZeneca valued at up to $18.5 billion, while Rongchang Biologics secured a $5.6 billion licensing deal with AbbVie, showcasing the global competitiveness of Chinese innovative drugs [4][10] Group 3 - The Chinese innovative drug industry is entering a commercialization phase, with over 70% of innovative drug companies achieving positive revenue growth by 2025 [5][11] - BeiGene reported revenue exceeding 36 billion yuan, demonstrating strong commercialization capabilities [5][11] - Leading companies like Innovent Biologics and Rongchang Biologics have achieved annual breakeven, while Elysium has reported over 2 billion yuan in net profit attributable to shareholders, indicating a transition from R&D investment to performance realization [5][11] Group 4 - Open Source Securities expresses a positive outlook on the innovative drug sector and its supply chain (CXO + research services), as well as emerging national strategic industries such as AI, brain-computer interfaces, and biomanufacturing [5][11] - The Hong Kong pharmaceutical sector has adjusted for nearly two quarters, presenting an attractive investment opportunity [5][11] - Investors are encouraged to consider the Hong Kong Stock Connect Innovative Drug ETF (520880) and its associated funds, which focus on innovative drug research companies, with the top ten weighted stocks accounting for over 73% [5][11]

Core Viewpoint - The AI healthcare sector experienced a slight increase of 0.42% on February 10, with Zhejiang Shuju Culture leading the gains [1] Market Performance - The Shanghai Composite Index closed at 4128.37, up by 0.13% [1] - The Shenzhen Component Index closed at 14210.63, up by 0.02% [1] Capital Flow - The AI healthcare sector saw a net inflow of 811 million yuan from main funds, while retail investors experienced a net outflow of 561 million yuan [1] - Speculative funds had a net outflow of 251 million yuan [1]

Core Viewpoint - Hualan Co., Ltd. announced a collaboration between its wholly-owned subsidiary, Hainan Lingqing Smart Pharmaceutical Technology Co., Ltd., and a technical team led by former CTO of Insilico Liu Kaixian and Academician Liu Jun from the American Academy of Sciences to establish a joint venture focused on drug repurposing and pharmacovigilance services using knowledge graphs [1][2]. Group 1 - The joint venture will be controlled by Lingqing Smart and will be included in the company's consolidated financial statements [1]. - The venture aims to provide intelligent solutions for drug research and safety management by integrating heterogeneous data sources [1]. - The specific business scope will be defined according to the business registration information [1]. Group 2 - To enhance the long-term development motivation of the joint venture, the company plans to implement a performance-based partnership incentive arrangement linked to business targets [2]. - This incentive will involve transferring partnership shares through Holding Platform 1 to motivate key personnel and others who significantly contribute to the joint venture's development [2]. - The arrangement aims to align the interests of core personnel with the long-term success of the venture, promoting risk-sharing and long-term incentives [2].

Core Viewpoint - The Hong Kong stock market showed strong performance in the healthcare sector, particularly in innovative drugs and medical companies, with significant gains observed in various stocks [1] Group 1: Market Performance - The Hong Kong stock market experienced fluctuations but ultimately strengthened, with notable performances in the innovative drug and medical sectors [1] - Stocks such as CSPC Pharmaceutical Group and Innovent Biologics rose over 6%, while others like Zai Lab and WuXi Biologics increased by more than 5% [1] - The Hong Kong Stock Connect Medical ETF (159506) saw a rise of over 3% during trading [1] Group 2: Industry Insights - At the J.P. Morgan Healthcare Conference held in January, global pharmaceutical companies disclosed advanced research pipelines and significant business development transactions, creating clear order expectations for the CXO industry [1] - The penetration of AI in healthcare is accelerating, with applications expanding from smart consultations to chronic disease management, leading to a reevaluation of the value of internet healthcare platforms like Alibaba Health and JD Health [1] - Analysts suggest that the current healthcare sector presents multiple investment opportunities, with the CXO industry benefiting from a recovery in overseas orders and domestic capacity clearance [1] - The medical device sector is supported by domestic equipment upgrade policies and overseas market expansion, with cutting-edge areas like brain-computer interfaces and AI imaging continuously catalyzing growth [1] - Internet healthcare is optimizing operational efficiency against the backdrop of deepening medical insurance payment reforms, leading to a clearer profitability growth trajectory [1] Group 3: ETF Information - The Hong Kong Stock Connect Medical ETF (159506) closely tracks the Hang Seng Hong Kong Stock Connect Innovative Drug and Healthcare Index (HSSCHI) [2] - The index composition emphasizes companies with high R&D expenditure and innovative drug business, ensuring that companies with the lowest average R&D to revenue ratio over the past two years are excluded [2] - This innovative focus aids investors in accurately capturing investment opportunities within the Hong Kong pharmaceutical sector [2]